Therapeutic Nuclear Medicines Market (Size, Volume and Value) and GrowthPosted by ankush Nikam on April 5th, 2021 According to a new market study by Future Market Insights (FMI), the global therapeutic nuclear medicines market will expand at a healthy rate between 2018 and 2028. The growth of the market is majorly attributed to factors such as the growing acceptance rate of therapeutic nuclear medicines, also known as radiopharmaceuticals, among consumers and medical professionals. These medicines have proven to be largely free of negative side-effects and minimal risk factors. Furthermore, the rising prevalence of prostate cancer is acting as a major growth attribute to the market. As the per statistics of the U.K. cancer research organization, prostate cancer is the most prevalent cancer among men with over 47,151 cases being diagnosed in 2015. Likewise, the American Cancer Society states that prostate cancer is the most common cause of death in the US. As the demand for safer, reliable, and less harmful drugs continues to increase in cancer treatment, therapeutic nuclear medicines are finding significant adoption among cancer patients. Along similar lines, continually increasing incidence of bone metastases is also bolstering the growth of the market. “Owing to the stringent regulations by the US Food and Drugs Administration (FDA), market players are working on complying with the guidelines to receive approvals”, opines FMI analyst. Therapeutic Nuclear Medicines Market – Key Takeaways
Therapeutic Nuclear Medicines Market – Key Trends
Therapeutic Nuclear Medicines Market – Regional Analysis
Therapeutic Nuclear Medicines Market – Competitive Landscape Key players operating in the market include some of the key players profiled in the therapeutic nuclear medicines market report include Bayer AG, Novartis AG, GE Healthcare, Curium Pharmaceuticals, Jubilant DraxImage, Spectrum Pharmaceuticals, Progenics Pharmaceuticals, Inc., ANSTO, Lantheus Medical Imaging, Inc., Eckert & Ziegler and International Isotopes Inc. The competitive landscape represents a highly consolidated structure with the top three players – GE Healthcare, Novartis AG, and Bayer accounting for nearly 87% of market share. For information on the Research Approach used in the Report, Request Methodology@ https://www.futuremarketinsights.com/askus/rep-gb-2930 Therapeutic Nuclear Medicines Market – Taxonomy Treatment type:
Indication:
Distribution channel:
Get Valuable Insights into the Therapeutic Nuclear Medicines Market Future Market Insights, in its new offering, provides an unbiased analysis of the global therapeutic nuclear medicines market, presenting historical demand data and forecast statistics for the period from 2018-2028. The study divulges compelling insights on the therapeutic nuclear medicines market, allowing readers to glean qualitative and quantitative information which will enable them to make informed market decisions in the upcoming forecast period. Like it? Share it!More by this author |